Citation Impact
Citing Papers
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
2013 StandoutScience
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
2013
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
2012
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2009
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer
2013
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
2011
High burden and pervasive positive selection of somatic mutations in normal human skin
2015 StandoutScience
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
2013
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Hallmarks of Cancer: The Next Generation
2011 Standout
Cancer statistics, 2017
2017 Standout
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
2010
John Snow's legacy: epidemiology without borders
2013 StandoutNobel
Trametinib (GSK1120212) in the treatment of melanoma
2013
MEK1/2 inhibitors in the treatment of gynecologic malignancies
2014
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
A view on drug resistance in cancer
2019 StandoutNature
Analysis of the genome to personalize therapy for melanoma
2010
Multifunctional Lipid/Quantum Dot Hybrid Nanocontainers for Controlled Targeting of Live Cells
2006 StandoutNobel
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
2014
Tumor adaptation and resistance to RAF inhibitors
2013
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
2014
The biology and management of non-small cell lung cancer
2018 StandoutNature
Lessons from the Cancer Genome
2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
2013
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
2010
Improving de novo protein binder design with deep learning
2023 StandoutNobel
Toll-like receptors and cancer
2008
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
2010
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology
2010
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
2013 Nature
New horizons in adjuvants for vaccine development
2020
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Imaging of autoimmune encephalitis – Relevance for clinical practice and hippocampal function
2015
Mitochondria: In Sickness and in Health
2012 Standout
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
Pancreatic Adenocarcinoma
2014 Standout
Antiangiogenic therapy—evolving view based on clinical trial results
2012
A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells
2014 StandoutNobel
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Dendritic cells in cancer immunotherapy
2010
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
2003
New horizons in adjuvants for vaccine development
2008
Immunity, Inflammation, and Cancer
2010 Standout
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
2013
Emerging Biological Principles of Metastasis
2017 Standout
Antigens for cancer immunotherapy
2008
Emerging Role of mTOR in the Response to Cancer Therapeutics
2016
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
2017
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
EMT: 2016
2016 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
A Hybrid Nanoparticle Probe for Dual‐Modality Positron Emission Tomography and Magnetic Resonance Imaging
2008
Cancer immunotherapy comes of age
2011 StandoutNature
A cornucopia of human polyomaviruses
2013
Rapid, microwave-assisted organic synthesis of selective V600EBRAF inhibitors for preclinical cancer research
2012
Prospects for MEK inhibitors for treating cancer
2014
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
The PI3K Pathway in Human Disease
2017 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Discovery and saturation analysis of cancer genes across 21 tumour types
2014 StandoutNature
MEK Inhibition in the Treatment of Advanced Melanoma
2013
Development of SM5-1-conjugated ultrasmall superparamagnetic iron oxide nanoparticles for hepatoma detection
2008
The BCL-2 Family Reunion
2010
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
2009
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
Copper is required for oncogenic BRAF signalling and tumorigenesis
2014 Nature
Sex Is an Independent Prognostic Indicator for Survival and Relapse/Progression-Free Survival in Metastasized Stage III to IV Melanoma: A Pooled Analysis of Five European Organisation for Research and Treatment of Cancer Randomized Controlled Trials
2013
Antibody-Mediated Encephalitis
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
2009
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Intracellular Delivery of a Proapoptotic Peptide via Conjugation to a RAFT Synthesized Endosomolytic Polymer
2009
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
2011 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015
Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
2005 StandoutNobel
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
2010
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
2010
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
2009
GABA B receptor autoantibody frequency in service serologic evaluation
2013
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
2009
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance
2010 StandoutNobel
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
2017
Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy
2016
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Immune Therapy for Cancer
2008
Unveiling the Mechanisms of Cell-Cell Fusion
2005 Science
Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma
2013
Works of Uwe Trefzer being referenced
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview
2003
Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
2008
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma
2003
Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma
2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
2011
Multimodal fusion imaging ensemble for targeted sentinel lymph node management: initial results of an innovative promising approach for anatomically difficult lymphatic drainage in different tumour entities
2006
GABAB receptor antibodies in paraneoplastic cerebellar ataxia
2013
SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions
2000
Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients
2004
Cytokine therapy in dermatology
2002
HLA-B8 association with late-stage melanoma – an immunological lesson?
2006
Hybrid-Cell Vaccines for Cancer Immune Therapy
2003
Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma
2000
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group
2006
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
2009
Immunogenicity of Constitutively Active V599EBRaf
2004
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
2012